teprotumumab sell brand name tepezza medic use treat adult thyroid eye diseas rare condit muscl fatti tissu behind eye becom inflam caus eye bulg outward common side effect muscl spasm nausea hair loss diarrhea fatigu high blood sugar hear loss dri skin alter sens tast headach teprotumumab use pregnant woman childbear potenti pregnanc status verifi prior begin treatment counsel pregnanc prevent treatment six month follow last dose human monoclon antibodi develop genmab rochecit need bind igfr teprotumumab approv use unit state januari food drug administr fda consid firstinclass medic multicent random trial patient activ grave ophthalmopathi teprotumumab effect placebo februari horizon announc result phase iii confirmatori trial evalu teprotumumab treatment activ thyroid eye diseas te studi meet primari endpoint show patient treat teprotumumab compar placebo meaning improv proptosi bulg eye percent teprotumumab patient compar percent placebo patient achiev primari endpoint mm reduct proptosi proptosi main caus morbid te secondari endpoint also meet safeti profil consist phase ii studi teprotumumab te juli horizon submit biolog licens applic bla fda teprotumumab treatment activ thyroid eye diseas te horizon request prioriti review applic grant fda day review period decid would result max month review process teprotumumabtrbw approv use unit state januari treatment adult thyroid eye diseas teprotumumab first investig treatment solid hematolog tumor includ breast cancer hodgkin nonhodgkin lymphoma nonsmal cell lung cancer sarcoma although result phase earli phase ii trial show promis research indic discontinu roch phase ii trial still progress allow complet develop halt due busi priorit rather safeti concern teprotumumab subsequ licens river vision develop corpor research treatment ophthalm condit horizon pharma horizon therapeut hereon horizon acquir rvdc continu clinic trial phase iii trial grave ophthalmopathi also know thyroid eye diseas te phase diabet macular edema grant breakthrough therapi orphan drug status fast track design fda grave ophthalmopathi teprotumumabtrbw approv base result two clinic trial trial nct trial nct subject activ thyroid eye diseas random either receiv teprotumumabtrbw placebo subject administ tepezza studi studi demonstr great two millimet reduct proptosi eye protrus compar subject receiv placebo respect trial conduct site europ unit state food drug administr fda grant applic teprotumumabtrbw fast track design breakthrough therapi design prioriti review design orphan drug design fda grant approv tepezza horizon therapeut ireland dac mexi melanoma ecromeximab